Cargando…

Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70

Hypervariable region 1 (HVR1), located in the N‐terminal region of a putative second envelope glycoprotein (gp70) of hepatitis C virus (HCV), contains immunological B‐cell epitopes which might be neutralizing epitopes. To clarify whether B‐cell epitopes within HVR1 are common among virus isolates or...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Nobuyuki, Nakazawa, Takahide, Ootsuyama, Yuko, Sugiyama, Kazuo, Ohkoshi, Showgo, Shimotohno, Kunitada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1994
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919351/
https://www.ncbi.nlm.nih.gov/pubmed/7525524
http://dx.doi.org/10.1111/j.1349-7006.1994.tb02894.x
_version_ 1783317606362513408
author Kato, Nobuyuki
Nakazawa, Takahide
Ootsuyama, Yuko
Sugiyama, Kazuo
Ohkoshi, Showgo
Shimotohno, Kunitada
author_facet Kato, Nobuyuki
Nakazawa, Takahide
Ootsuyama, Yuko
Sugiyama, Kazuo
Ohkoshi, Showgo
Shimotohno, Kunitada
author_sort Kato, Nobuyuki
collection PubMed
description Hypervariable region 1 (HVR1), located in the N‐terminal region of a putative second envelope glycoprotein (gp70) of hepatitis C virus (HCV), contains immunological B‐cell epitopes which might be neutralizing epitopes. To clarify whether B‐cell epitopes within HVR1 are common among virus isolates or specific for the homologous virus isolate, we examined the reactivities of sera from 53 patients with chronic hepatitis or hepatocellular carcinoma/liver cirrhosis against two different HVR1 peptides (HVR11‐1 and HVR1 Y‐l) derived from patient I with sporadic acute hepatitis and an asymptomatic carrier Y, respectively, using our original assay system for the detection of anti‐HVR1 antibody. All patients examined had a history of blood transfusion. Most sera showed no reactivity with either HVR1 1‐1 or HVR1 Y‐l peptide. Only seven and fourteen serum samples reacted significantly, although weakly, with HVR1 1‐1 and HVR1 Y‐l peptides, respectively, compared with the serum from patient I or asymptomatic carrier Y. The blood transfusions of most reactive cases had occurred more than thirty years earlier. Six cases reacted with both HVR1 1‐1 and HVR1 Y‐l peptides, but further analysis revealed that only three cases reacted weakly with the peptide for either epitope I or II, identified within HVR11‐1, These results indicate that the B‐cell epitopes within HVR1 are fairly specific for the homologous virus isolate, and this may represent a serious difficulty in the development of a vaccine against HCV.
format Online
Article
Text
id pubmed-5919351
institution National Center for Biotechnology Information
language English
publishDate 1994
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-59193512018-05-11 Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70 Kato, Nobuyuki Nakazawa, Takahide Ootsuyama, Yuko Sugiyama, Kazuo Ohkoshi, Showgo Shimotohno, Kunitada Jpn J Cancer Res Article Hypervariable region 1 (HVR1), located in the N‐terminal region of a putative second envelope glycoprotein (gp70) of hepatitis C virus (HCV), contains immunological B‐cell epitopes which might be neutralizing epitopes. To clarify whether B‐cell epitopes within HVR1 are common among virus isolates or specific for the homologous virus isolate, we examined the reactivities of sera from 53 patients with chronic hepatitis or hepatocellular carcinoma/liver cirrhosis against two different HVR1 peptides (HVR11‐1 and HVR1 Y‐l) derived from patient I with sporadic acute hepatitis and an asymptomatic carrier Y, respectively, using our original assay system for the detection of anti‐HVR1 antibody. All patients examined had a history of blood transfusion. Most sera showed no reactivity with either HVR1 1‐1 or HVR1 Y‐l peptide. Only seven and fourteen serum samples reacted significantly, although weakly, with HVR1 1‐1 and HVR1 Y‐l peptides, respectively, compared with the serum from patient I or asymptomatic carrier Y. The blood transfusions of most reactive cases had occurred more than thirty years earlier. Six cases reacted with both HVR1 1‐1 and HVR1 Y‐l peptides, but further analysis revealed that only three cases reacted weakly with the peptide for either epitope I or II, identified within HVR11‐1, These results indicate that the B‐cell epitopes within HVR1 are fairly specific for the homologous virus isolate, and this may represent a serious difficulty in the development of a vaccine against HCV. Blackwell Publishing Ltd 1994-10 /pmc/articles/PMC5919351/ /pubmed/7525524 http://dx.doi.org/10.1111/j.1349-7006.1994.tb02894.x Text en
spellingShingle Article
Kato, Nobuyuki
Nakazawa, Takahide
Ootsuyama, Yuko
Sugiyama, Kazuo
Ohkoshi, Showgo
Shimotohno, Kunitada
Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70
title Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70
title_full Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70
title_fullStr Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70
title_full_unstemmed Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70
title_short Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70
title_sort virus isolate‐specific antibodies against hypervariable region 1 of the hepatitis c virus second envelope protein, gp70
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919351/
https://www.ncbi.nlm.nih.gov/pubmed/7525524
http://dx.doi.org/10.1111/j.1349-7006.1994.tb02894.x
work_keys_str_mv AT katonobuyuki virusisolatespecificantibodiesagainsthypervariableregion1ofthehepatitiscvirussecondenvelopeproteingp70
AT nakazawatakahide virusisolatespecificantibodiesagainsthypervariableregion1ofthehepatitiscvirussecondenvelopeproteingp70
AT ootsuyamayuko virusisolatespecificantibodiesagainsthypervariableregion1ofthehepatitiscvirussecondenvelopeproteingp70
AT sugiyamakazuo virusisolatespecificantibodiesagainsthypervariableregion1ofthehepatitiscvirussecondenvelopeproteingp70
AT ohkoshishowgo virusisolatespecificantibodiesagainsthypervariableregion1ofthehepatitiscvirussecondenvelopeproteingp70
AT shimotohnokunitada virusisolatespecificantibodiesagainsthypervariableregion1ofthehepatitiscvirussecondenvelopeproteingp70